Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
- 11 August 2005
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 55 (6) , 684-698
- https://doi.org/10.1007/s00262-005-0047-0
Abstract
Cytokine shedding by tumor cells into the local microenvironment modulates host immune response, tumor growth, and metastasis. The study aimed to verify the hypothesis that the immunological microenvironment of pancreatic carcinoma exists in a prevalently immunosuppressive state, influencing survival. We analyzed expression profiles of pro-inflammatory (IL-1β, IL-2, IL-6, IL-8, IL-12 p40, IL-18 and IFN-γ) and anti-inflammatory (IL-10, IL-11, IL-13 and TGF-β isoforms) cytokines. The study was performed both in vitro, in five pancreatic carcinoma cell lines (real time RT-PCR), and in specimens from 65 patients, comparing tumoral versus non-tumoral pancreatic tissues (real time RT-PCR and immunohistochemistry). Furthermore, cytokines were measured in supernatants and sera (from patients and controls) by ELISA. All cell lines expressed IL-8, IL-18, TGF-β1, TGF-β2 and TGF-β3, but not IFN-γ and IL-2 transcripts. Expression of IL-1β, IL-6, IL-10, IL-11, IL-13 and IL-12 mRNA was variable. All the above cytokines were detected as soluble proteins in supernatants, except IL-13. Tumor tissues overexpressed IL-1β, IL-6, IL-8, IL-10, IL-11, IL-12 p40, IL-18, IFN-γ, TGF-β1, TGF-β2 and TGF-β3 at the mRNA level and IL-1β, IL-18, TGF-β2 and TGF-β3 also at the protein level. Conversely, non-tumor tissues had stronger RNA and protein expression of IL-13. Survival was significantly longer in patients with high IL-1β and IL-11 and moderate IL-12 expression. Serum IL-8, IL-10, IL-12, IL-18, TGF-β1 and TGF-β2 were higher in patients than in controls, as opposed to IL-1β and IL-13. Patients with low circulating levels of IL-6, IL-18 and TGF-β2 survived longer. Pancreatic cancer is characterized by peculiar cytokine expression patterns, associated with different survival probabilities.Keywords
This publication has 50 references indexed in Scilit:
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCRNucleic Acids Research, 2002
- The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancerOncogene, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Expression of MHC class I and class II antigens in pancreatic adenocarcinomasTissue Antigens, 1996
- Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinomaInternational Journal of Cancer, 1995
- Cloning of a new cytokine that induces IFN-γ production by T cellsNature, 1995
- Expression of Leukemia Inhibitory Factor and Interleukin-11 by Human Melanoma Cell Lines: LIF, IL-6, and IL-11 Are Not CoregulatedJournal of Interferon & Cytokine Research, 1995
- The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimerEuropean Journal of Immunology, 1993
- Production of Multiple Growth Factors by a Newly Established Human Thyroid Carcinoma Cell LineJapanese Journal of Cancer Research, 1992